PubRank

Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children

Clinical Trial ID NCT02360696

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02360696

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001 132.88
2 Functional gastroduodenal disorders. Gastroenterology 2006 8.51
3 Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med 2003 7.51
4 Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007 2.44
5 Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008 2.24
6 Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009 1.90
7 Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2005 1.58
8 Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy 2009 1.44
9 Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis. Dig Dis Sci 2001 1.39
10 Treatment of eosinophilic gastroenteritis with montelukast. J Allergy Clin Immunol 1999 1.32
11 Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010 1.20
12 Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009 1.15
13 Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 1999 1.10
14 Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006 1.09
15 Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease. Thorax 2001 1.08
16 Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther 2007 1.04
17 Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol 2009 0.99
18 Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol 2003 0.98
19 Antral inflammatory cells, gastric emptying, and electrogastrography in pediatric functional dyspepsia. Dig Dis Sci 2008 0.97
20 Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 2007 0.97
21 Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr 2004 0.96
22 Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 1999 0.96
23 Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr 2010 0.95
24 Montelukast: use in pediatric patients with eosinophilic gastrointestinal disease. J Pediatr Gastroenterol Nutr 2003 0.95
25 The response to anti-TNF-alpha treatment: gene regulation at the bedside. Rheumatology (Oxford) 2005 0.93
26 Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann Allergy Asthma Immunol 2005 0.91
27 Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr Drugs 2002 0.89
28 Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol 2010 0.88
29 Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila) 2006 0.87
30 Variations in psychological profile among children with recurrent abdominal pain. J Clin Psychol Med Settings 2008 0.87
31 The role of pharmacogenomics in improving the management of asthma. J Allergy Clin Immunol 2010 0.85
32 Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 2005 0.85
33 Activated duodenal mucosal eosinophils in children with dyspepsia: a pilot transmission electron microscopic study. J Pediatr Gastroenterol Nutr 2002 0.84
34 Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 1997 0.84
35 Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos 2011 0.82
36 Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 2010 0.82
37 Regulation of monocyte chemoattractant protein 1 by cysteinyl leukotriene D4 in human lung epithelial A549 cells. Ann Allergy Asthma Immunol 2009 0.75
38 Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. J Allergy Clin Immunol 2003 0.75
39 Leukotriene pathway polymorphisms are associated with altered cysteinyl leukotriene production in children with acute asthma. Prostaglandins Leukot Essent Fatty Acids 2009 0.75
Next 100